Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Galectin 3
54%
Biological Marker
31%
Disease
20%
Cardiovascular Disease
19%
Mouse
16%
Malignant Neoplasm
15%
Heart Failure with Preserved Ejection Fraction
12%
Fibrosis
12%
Heart Muscle Fibrosis
12%
Immune Checkpoint Inhibitor
10%
Inflammation
10%
Heart Failure with Reduced Ejection Fraction
10%
Heart Infarction
9%
Natriuretic Factor
9%
Myocarditis
7%
Heart Ventricle Remodeling
6%
Brain Natriuretic Peptide
6%
Comorbidity
5%
Clinical Trial
5%
C57BL 6 Mouse
5%
Creatinine
5%
Medicine and Dentistry
Heart Failure
44%
Biological Marker
19%
Malignant Neoplasm
18%
Galectin 3
16%
Heart Failure with Reduced Ejection Fraction
14%
Cardiovascular System
11%
Heart Failure with Preserved Ejection Fraction
11%
Hazard Ratio
10%
Ejection Fraction
9%
Cardiovascular Disease
9%
Cardiology
9%
Disease
8%
Natriuretic Factor
7%
Population
7%
Heart Left Ventricle Ejection Fraction
6%
Brain Natriuretic Peptide
6%
Cardiac Fibrosis
6%
Keyphrases
Heart Failure
38%
Galectin-3 (Gal-3)
27%
Heart Failure with Preserved Ejection Fraction (HFpEF)
11%
Patients with Heart Failure
9%
Heart Failure Patients
8%
Obesity
8%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
7%
Biomarkers in Heart Failure
7%
Heart Disease
7%
Cardiovascular Disease
6%
Natriuretic Peptides
6%
New-onset Heart Failure
5%
Incident Cancer
5%